• Adam M Deane, Marianne J Chapman, Reintam Blaser Annika A Department of Anaesthesiology and Intensive Care, University of Tartu, Tartu, Estonia. , Stephen A McClave, and Anton Emmanuel.
• Intensive Care Unit, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
• Nutr Clin Pract. 2019 Feb 1; 34 (1): 23-36.

AbstractGastrointestinal dysmotility causes delayed gastric emptying, enteral feed intolerance, and functional obstruction of the small and large intestine, the latter functional obstructions being frequently termed ileus and Ogilvie syndrome, respectively. In addition to meticulous supportive care, drug therapy may be appropriate in certain situations. There is, however, considerable variation among individuals regarding what gastric residual volume identifies gastric dysmotility and would encourage use of a promotility drug. While the administration of either metoclopramide or erythromycin is supported by evidence it appears that, dual-drug therapy (erythromycin and metoclopramide) reduces the rate of treatment failure. There is a lack of evidence to guide drug therapy of ileus, but neither erythromycin nor metoclopramide appear to have a role. Several drugs, including ghrelin agonists, highly selective 5-hydroxytryptamine receptor agonists, and opiate antagonists are being studied in clinical trials. Neostigmine, when infused at a relatively slow rate in patients receiving continuous hemodynamic monitoring, may alleviate the need for endoscopic decompression in some patients.© 2018 American Society for Parenteral and Enteral Nutrition.

17 keywords...

hide…